These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31929384)

  • 1. Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case.
    Whiteway SL; Betts AM; O'Neil ER; Green AL; Gilani A; Orr BA; Mathis DA
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e813-e818. PubMed ID: 31929384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
    Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
    J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
    Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
    Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3).
    Coccé MC; Mardin BR; Bens S; Stütz AM; Lubieniecki F; Vater I; Korbel JO; Siebert R; Alonso CN; Gallego MS
    Genes Chromosomes Cancer; 2016 Sep; 55(9):677-87. PubMed ID: 27121553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targetable molecular alterations in congenital glioblastoma.
    Gilani A; Donson A; Davies KD; Whiteway SL; Lake J; DeSisto J; Hoffman L; Foreman NK; Kleinschmidt-DeMasters BK; Green AL
    J Neurooncol; 2020 Jan; 146(2):247-252. PubMed ID: 31875306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GOPC-ROS1 mosaicism in agminated Spitz naevi: report of two cases.
    Goto K; Pissaloux D; Kauer F; Huriet V; Tirode F; de la Fouchardière A
    Virchows Arch; 2021 Sep; 479(3):559-564. PubMed ID: 33733342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report.
    Wang J; Luo S; Li Y; Zheng H
    Medicine (Baltimore); 2021 Jan; 100(3):e24377. PubMed ID: 33546077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
    Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
    Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
    Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
    Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
    Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
    J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
    Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
    Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
    Aljohani H; Koncar RF; Zarzour A; Park BS; Lee SH; Bahassi el M
    Oncotarget; 2015 Aug; 6(24):20388-95. PubMed ID: 25978031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
    Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
    Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme.
    Lim SM; Choi J; Chang JH; Sohn J; Jacobson K; Policht F; Schulz J; Cho BC; Kim SH
    PLoS One; 2015; 10(9):e0137678. PubMed ID: 26366867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and epigenomic re-categorization of congenital glioblastoma and desmoplastic infantile ganglioglioma.
    Gilani A; Siddiq Z; Kissell E; Kasson J; Kleinschmidt-DeMasters BK
    Childs Nerv Syst; 2023 Jul; 39(7):1861-1868. PubMed ID: 36707425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.
    Karayan-Tapon L; Cortes U; Rivet P; Jermidi C; Vassal G; Wager M; Taillandier L
    Eur J Cancer; 2014 Sep; 50(13):2364-6. PubMed ID: 24999209
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
    Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
    Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.
    O'Neil SR; Weber GA; Deming DA; Burkard ME; Kenny PA; Richmond CS; Parsons BM
    JCO Precis Oncol; 2023 Jul; 7():e2300174. PubMed ID: 37487149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.